Advicenne Announces First Patient Enrolled in US ARENA-2 Pivotal Phase III Clinical Trial Evaluating ADV7103 in distal Renal Tubular Acidosis (dRTA)
August 29, 2019
Advicenne (Euronext Paris & Brussels: ADVIC – FR0013296746), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare kidney disease, today announced the enrollment of the first patient in its ARENA-2 study, currently being conducted in the United States. The pivotal Phase III clinical trial evaluates Advicenne’s lead drug candidate, ADV7103, in the treatment of distal Renal Tubular Acidosis (dRTA).